

To Be Mailed

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/405		A1	(11) International Publication Number: WO 99/42102 (43) International Publication Date: 26 August 1999 (26.08.99)																					
(21) International Application Number: PCT/US99/03906		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).																						
(22) International Filing Date: 23 February 1999 (23.02.99)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>																						
(30) Priority Data: 60/075,555 23 February 1998 (23.02.98) US 60/112,565 16 December 1998 (16.12.98) US																								
(71) Applicants: SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION [US/US]; P.O. Box U-1060, Mobile, AL 36688 (US). NEW YORK UNIVERSITY [US/US]; 70 Washington Square South, New York, NY 10012 (US).																								
(72) Inventor: PAPPOLLA, Miguel, A.; Apartment 1128, 1500 Hillcrest Road, Mobile, AL 36695 (US).																								
(74) Agent: ROGALSKYJ, Peter; Braman & Rogalskyj, LLP, P.O. Box 352, Canandaigua, NY 14424-0352 (US).																								
(54) Title: INDOLE-3-PROPIONIC ACIDS, SALTS AND ESTERS THEREOF USED AS MEDICAMENTS																								
(57) Abstract																								
<p>The cytotoxic effects of amyloid beta protein on cells are prevented by contacting the cells with an effective amount of an indole-3-propionic acid or a salt or ester thereof. Furthermore, a fibrillogenic disease can be treated in a human subject by administering to the human subject an amount of an indole-3-propionic acid or a salt or ester thereof effective to prevent or reverse fibrillogenesis. Oxidation in a biological sample can be decreased by contacting the biological sample with an effective amount of an indole-3-propionic acid or a salt or ester thereof. Additionally, diseases or other conditions where free radicals and/or oxidative stress play a role can be treated by administering an effective amount of an indole-3-propionic acid or a salt or ester thereof.</p>																								
<table border="1"><caption>Data from Bar Chart</caption><thead><tr><th>AB25-35 (μM)</th><th>Treatment</th><th>% Cell Viability</th></tr></thead><tbody><tr><td>0</td><td>NONE</td><td>100</td></tr><tr><td>0</td><td>3IPA</td><td>75</td></tr><tr><td>0</td><td>PBN</td><td>105</td></tr><tr><td>50</td><td>NONE</td><td>115</td></tr><tr><td>50</td><td>3IPA</td><td>110</td></tr><tr><td>50</td><td>PBN</td><td>115</td></tr></tbody></table>				AB25-35 (μM)	Treatment	% Cell Viability	0	NONE	100	0	3IPA	75	0	PBN	105	50	NONE	115	50	3IPA	110	50	PBN	115
AB25-35 (μM)	Treatment	% Cell Viability																						
0	NONE	100																						
0	3IPA	75																						
0	PBN	105																						
50	NONE	115																						
50	3IPA	110																						
50	PBN	115																						

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INDOLE-3-PROPIONIC ACIDS, SALTS AND ESTERS THEREOF USED AS MEDICAMENTS

The present application claims priority from
5 U.S. Provisional Patent Application Serial No.
60/075,555, filed February 23, 1998, and from U.S.
Provisional Patent Application Serial No. 60/112,565,
filed December 16, 1998.

Throughout this application, various
10 publications are referenced, many in parenthesis. Full
citations for these publications are provided at the
end of each part of the application. The disclosures
of these publications in their entireties are hereby
incorporated by reference in this application.

15

FIELD OF THE INVENTION

The present invention relates to a use of
indole-3-propionic acid and, more particularly, to the
20 use of indole-3-propionic acid to prevent cytotoxic
effects of amyloid beta protein, to treat fibrillrogenic
diseases, to decrease oxidation in biological samples,
and to treat diseases or other conditions where free
radicals and/or oxidative stress play a role.

25

BACKGROUND OF THE INVENTION

It is estimated that ten percent of persons
older than 65 years of age have mild to severe
30 dementia. Alzheimer's Disease ("AD") is the most
common cause of chronic dementia with approximately two
million people in the United States having the disease.
Although once considered a condition of middle age, it
is now known that the histopathologic lesions of
35 Alzheimer's Disease (i.e., neuritic amyloid plaques,
neurofibrillary degeneration, and granulovascular
neuronal degeneration) are also found in the brains of
elderly people with dementia. The number of such

- 2 -

lesions correlates with the degree of intellectual deterioration. This high prevalence, combined with the rate of growth of the elderly segment of the population, make dementia (and particularly AD) one of 5 the most important current public health problems.

Deposition of cerebral amyloid is a primary neuropathologic marker of Alzheimer's Disease. The amyloid is composed of a 40-42 amino acid peptide called the amyloid beta protein ("A β ") (Glenner and 10 Wong, 1984). Amyloid deposits in AD are found mainly as components of senile plaques, and in the walls of cerebral and meningeal blood vessels (Robakis and Pangalos, 1994).

Molecular cloning showed that A β comprises a 15 small region of a larger amyloid precursor protein ("APP") (Robakis et al., 1987; Weidemann et al., 1989). Briefly, this is a type I integral membrane glycoprotein having a large extracytoplasmic portion, a smaller intracytoplasmic region, and a single 20 transmembranous domain. APP undergoes extensive post-translational modifications (Pappolla and Robakis, 1995; Robakis and Pangalos, 1994) prior to the secretion of its N-terminal portion (Sambamurti et al., 1992; Robakis and Pangalos, 1994). Physiologic 25 processing of APP involves cleavage within the A β sequence by an unidentified enzyme, alpha-secretase (Anderson et al., 1991). Smaller quantities of APP molecules are cleaved at two other sites that could potentially produce amyloidogenic secreted or membrane 30 bound APP (Robakis and Pangalos, 1994). A β is also produced during normal cellular metabolism (Haass et al., 1992; Shoji et al., 1992).

There is some controversy as to whether amyloid causes AD; however, three main lines of

- 3 -

evidence have strengthened the amyloid hypothesis. The first piece of evidence is provided by the identification of several point mutations within the APP gene. These mutations segregate within a subgroup of patients afflicted with a familial form of the disorder and thus suggest a pathogenetic relationship between the APP gene and AD (Chartier-Harlin et al., 1991; Kennedy et al., 1993). Secondly, amyloid deposition temporally precedes the development of neurofibrillary changes (Pappolla et al., 1996) and this observation is also consistent with a link between amyloid and neuronal degeneration. Finally, it has been shown that A β is toxic to neurons (Yankner et al., 1990; Behl et al., 1992; Behl et al., 1994; Zhang et al., 1994), a finding that also strengthened the hypothesis that the amyloid peptide may contribute to the neuronal pathology in AD.

The finding that A β has neurotoxic properties has provided a possible connection between amyloid accumulation and neurodegeneration. Because of the close association between aging and AD and the similarities in the neuropathology of both conditions, oxidative stress has been proposed to play a role in the pathogenesis of AD lesions.

Several investigators demonstrated that oxygen free-radicals ("OFRs") are related to the cytotoxic properties of A β (Behl, 1992; Behl, 1994; Harris et al., 1995; Butterfield et al., 1994; Goodman and Mattson, 1994). Such findings are important, since markers of oxidative injury are topographically associated with the neuropathologic lesions of AD (Pappolla et al., 1992; Furuta et al., 1995; Smith et al., 1995; Pappolla et al., 1996). Because of these observations, antioxidants have been proposed as

- 4 -

potential therapeutic agents in AD (Mattson, 1994; Hensley et al., 1994; Pappolla et al., 1996).

A need continues for methods of treating AD and other fibrillogenic diseases.

5

SUMMARY OF THE INVENTION

The present invention relates to a method of preventing cytotoxic effects of amyloid beta protein on 10 cells. The method includes contacting the cells with an effective amount of an indole-3-propionic acid or an ester or salt thereof.

The present invention further relates to a method of treating a fibrillogenic disease in a human 15 subject. The method includes administering, to the human subject, an amount of indole-3-propionic acid or an ester or salt thereof effective to inhibit or reverse fibrillogenesis.

The present invention also relates to a 20 method of decreasing oxidation in a biological sample. The method includes contacting the biological sample with an effective amount of a indole-3-propionic acid or a salt or ester thereof.

The present invention still further relates to 25 a method of treating diseases or other conditions where free radicals and/or oxidative stress play a role. The method includes administering, to the human subject, an amount of indole-3-propionic acid or an ester or salt thereof effective to treat such disease or condition.

30

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a bar graph illustrating 35 viabilities expressed as percentages using SK-N-SH human neuroblastoma cells exposed to either A β (25-35)

- 5 -

alone or in conjunction with IPA or PBN.

Figure 2 is a bar graph illustrating viabilities expressed as percentages using PC12 rat pheochromocytoma cells exposed to either A β (25-35) alone or in conjunction with IPA or PBN.

Figure 3 is a bar graph illustrating viabilities expressed as percentages using SK-N-SH human neuroblastoma cells exposed to either A β (1-42) alone or in conjunction with IPA or PBN.

Figure 4 is a bar graph illustrating the degree of lipid peroxidation (MDA measurement) induced by exposing cells to either amyloid peptide A β (1-42) or DDTc alone or each along with IPA.

Figure 5 is a bar graph showing the antioxidant activity of IPA by preventing cell death of PC12 rat neuroblastoma cells induced by inhibition of superoxide dismutase by DDTc.

Figures 6A and 6B are bar graphs showing the effect of IPA on β sheet formation upon incubation of A β (1-40) for 24 hours (Figure 6A) and 48 hours (Figure 6B).

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery that the natural compound indole-3-propionic acid ("IPA") has a combination of properties which render it particularly useful for preventing the cytotoxic effects of amyloid beta protein on cells, for treating any fibrillogenic disease, and for protecting cells from oxidative damage. Accordingly, the compounds of the present invention are powerful therapeutic agents in Alzheimer's Disease and other fibrillogenic diseases, such as, without limitation, prion-related diseases. It may also be used as a


- 6 -

therapeutic agent for the treatment of other diseases where free radicals and/or oxidative stress plays a role. These conditions include Parkinson's Disease, Lewy body dementia, amyotrophic lateral sclerosis, 5 progressive supranuclear palsy, other forms of amyloidoses, stroke, atherosclerosis, emphysema, and some forms of cancer. Furthermore, data show that IPA also has antifibrillrogenic activity.

The subject invention provides a method of 10 preventing cytotoxic effects of amyloid beta protein on cells. The method comprises exposing the cells to an effective amount of an indole-3-propionic acid or a salt or ester thereof.

As used herein, "amyloid beta protein" ("A β ") 15 refers to the 40-42 amino acid peptide that makes up the cerebral amyloid which is the primary neuropathologic marker of Alzheimer's Disease ("AD"), and refers to fragments of the A β capable of causing cytotoxic effects on cells. For example, one such 20 fragment of A β is the fragment made up of amino acid residues 25-35 of A β (see Glenner and Wong 1984 for the full amino acid sequence of A β , which is hereby incorporated by reference).

As used herein, indole-3-propionic acids are 25 meant to include compounds having the formula:



where R¹, R², R³, R⁴, R⁵, and R⁶ are independently selected from the group consisting of hydrogen,

substituted alkyl groups, unsubstituted alkyl groups, substituted aryl groups, unsubstituted aryl groups, alkoxy groups, substituted or unsubstituted amino groups, thiol groups, alkylthio groups, arylthio groups, and the like. Preferably, R⁵ and R⁶ are hydrogen. One example of a suitable indole-3-propionic acid is indole-3-propionic acid, which has the above formula where each of R¹, R², R³, R⁴, R⁵, and R⁶ is a hydrogen atom. Preferred substituents are those which do not significantly affect the antioxidant and antifibrillrogenic properties of the indole-3-propionic acids, as described in more detail below. Other preferred substituents are those which enhance brain-penetration, such as a covalently bonded lipophilic moiety. These substituents can be present on any atom of the indole nucleus which has an available hydrogen. The mode of attachment of the lipophilic moiety is not critical, and can be effected by a carbon-carbon, carbon-oxygen, carbon-nitrogen, or carbon-sulfur bond. To maximize the lipophilicity of the resulting compound, however, it is preferred that attachment be effected so as to minimize polarity. Consequently, it is preferred that the lipophilic moiety be attached via a carbon-carbon bond. The lipophilic moiety can be a hydrocarbon, such as an alkyl having from 5 to 20 carbons. These alkyls can be unsubstituted, such as hexyl or dodecyl, or substituted, such as with an aryl moiety, as in the case where the substituted alkyl is a benzyl or a phenylethyl group. Alternatively, the lipophilic moiety can be substituted or unsubstituted homocyclic rings, such as phenyl groups or a tolyl groups, homocyclic ring systems, heterocyclic rings, heterocyclic ring systems, or multicyclic lipophilic "cage" moieties, such as adamantine. In particular,

the use of the multicyclic "cage" compounds are particularly advantageous (Tsuzuki, 1991).

Some indole-3-propionic acids can be obtained commercially. Others can be prepared by modifications 5 to conventional procedures for the preparation of indole-3-propionic acid, such as the ones described in Johnson and Crosby, 1969) and in U.S. Patent No. 5,300,506, U.S. Patent No. 5,077,293, and JP 03/127,732, each of which are hereby incorporated by 10 reference.

As indicated above, the present invention can also be carried out using salts of the above-described indole-3-propionic acids. Suitable salts include, for example, pharmaceutically acceptable salts, such as 15 sodium salts, potassium salts, and ammonium salts. Salts of indole-3-propionic acid can be made by conventional methods from the corresponding indole-3-propionic acid by mixing the an aqueous solution or dispersion of the acid with an appropriate base (e.g., 20 sodium, potassium, or ammonium hydroxide, or sodium or potassium carbonate).

In addition, also as indicated above, the present invention can be carried out using esters of the above-described indole-3-propionic acids. Examples of such 25 esters include methyl ester, ethyl ester, propyl ester, benzyl ester, and the like. Indole-3-propionic acid esters bearing a lipophilic ester moiety, such as those described above, can also be used advantageously to increase the brain penetration of the indole-3-propionic acid ester. Indole-3-propionic acid esters 30 can be prepared from their corresponding acids or salts by a variety of methods known to those skilled in the art, such as, for example, by first transforming the acid to the acid chloride and then reacting the acid

- 9 -

chloride with a suitable alcohol. Other suitable methods for making esters are described in Kemp and Vellaccio, 1980.

Preferably, the indole-3-propionic acid, 5 salt, or ester has antioxidative and/or antifibrilllogenic properties and/or prevents the cytotoxic effects of A β . Various indole-3-propionic acids, salts, and esters can readily be assayed to ensure that the function of preventing the cytotoxic 10 effects of A β is retained using the methodology disclosed herein, such as assays for cell viability, lipid peroxidation, intracellular Ca $^{2+}$, and oxygen free-radicals. The prevention of other cytotoxic effects of A β on cells can readily be observed microscopically, 15 such as the prevention of membrane blebbing, cell retraction, abnormal distribution of chromatin, and karyorrhexis. Antioxidation and antifibrilllogenic effects of the various indole-3-propionic acids can be assayed by conventional methods, such as those 20 described in the Examples of this application.

As indicated above, the cytotoxic or cell killing effects of A β include, for example, decreased cell viability (i.e., cell death), increased lipid peroxidation (an indicator of increased oxygen free-radicals), increased intracellular Ca $^{2+}$ levels, diffuse membrane blebbing, cell retraction, abnormal distribution of chromatin towards the nuclear membrane, and karyorrhexis. 25

The cytotoxic effects of A β are most readily seen in neuronal cells (including cells of the central and peripheral nervous systems), and occur in human subjects afflicted with fibrilllogenic diseases, such as Alzheimer's Disease. 30

The effective amount of the indole-3-

- 10 -

propionic acid (or salt or ester thereof) for prevention of the cytotoxic effects of A β can be readily determined by conventional methods known in the art, such as establishing dose-response curves, as 5 described below. It will be appreciated that the actual preferred amount of the indole-3-propionic acid (or salt or ester thereof) to be administered according to the present invention will vary according to the particular form of the indole-3-propionic acid (i.e., 10 whether it is a salt, an ester, or an acid), the particular composition formulated, and the mode of administration. Many factors that may modify the action of the indole-3-propionic acid (or salt or ester thereof) can be taken into account by those skilled in 15 the art; e.g., body weight, sex, diet, time of administration, route of administration, rate of excretion, condition of the subject, drug combinations, and reaction sensitivities and severities. Administration can be carried out continuously or 20 periodically within the maximum tolerated dose. Optimal administration rates for a given set of conditions can be ascertained by those skilled in the art using conventional dosage administration tests.

The invention further provides a method of 25 treating fibrillogenic diseases in a human subject. The method includes administering an amount of an indole-3-propionic acid or a salt or ester thereof effective to inhibit or reverse fibrillogenesis, i.e., inhibit or reverse fibril formation. As used herein, 30 "fibrillogenic diseases" are meant to include any disease or condition involving the undesirable deposition of fibrils. As non-limiting examples thereof, such diseases or conditions include disorders or diseases resulting from abnormal formation of

- 11 -

amyloid or amyloid-like deposits, such as, but not limited to, prion-related encephalopathies, Alzheimer's dementia or disease ("AD"), and other amyloidosis disorders. Examples of prion-related encephalopathies 5 include Creutzfeldt-Jakob disease ("CJD") and Gerstmann-Straussler-Scheinker disease ("GSS") in humans, scrapie in sheep and goats, and spongiform encephalopathy in cattle.

The present invention further provides a 10 method of treating diseases or other conditions where free radicals and/or oxidative stress play a role. The method includes administering an amount of an indole-3-propionic acid or a salt or ester thereof effective to treat the disease or condition. Diseases or conditions 15 where free radicals and/or oxidative stress play a role include, without limitation, Parkinson's Disease, Lewy body dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, emphysema, and some forms of cancer.

20 Since indole-3-propionic acid and salts and esters thereof are effective in treating diseases or other conditions where free radicals and/or oxidative stress play a role as well as preventing cytotoxic effects of amyloid beta protein on cells, these 25 compounds are expected to be particularly useful in treating diseases associated with the amyloid beta protein, such as AD.

For all of the indications of indole-3-propionic acid or a salt or ester thereof, suitable 30 dosage amounts are discussed above, and suitable routes of administration include systemic administration (particularly in cases where the indole-3-propionic acid or a salt or ester thereof employed is one which crosses the blood-brain barrier). Systemic

administration includes parenteral and oral administration, for example, as discussed in further detail below.

The indole-3-propionic acid or a salt or ester thereof can be administered alone or in combination with compatible carriers as a composition. Compatible carriers include suitable pharmaceutical carriers or diluents. The diluent or carrier ingredients should be selected so that they do not diminish the therapeutic effects of the indole-3-propionic acid or a salt or ester thereof as used in the present invention.

The compositions may be made up in any suitable form appropriate for the desired use; e.g., oral, parenteral, or topical administration. Suitable dosage forms for oral use include tablets, dispersible powders, granules, capsules, suspensions, syrups, elixirs, and skin patches. Inert diluents and carriers for tablets include, for example, calcium carbonate, sodium carbonate, lactose, and talc. Tablets may also contain granulating and disintegrating agents such as starch and alginic acid, binding agents such as starch, gelatin, and acacia, and lubricating agents such as magnesium stearate, stearic acid, and talc. Tablets may be uncoated or may be coated by known techniques to delay disintegration and absorption. Inert diluents and carriers which may be used in capsules include, for example, calcium carbonate, calcium phosphate, and kaolin. Suspensions, syrups, and elixirs may contain conventional excipients, for example, methyl cellulose, tragacanth, sodium alginate; wetting agents, such as lecithin and polyoxyethylene stearate; and preservatives, e.g., ethyl-p-hydroxybenzoate.

Dosage forms suitable for parenteral

- 13 -

administration include solutions, suspensions, dispersions, emulsions, and the like. They may also be manufactured in the form of sterile solid compositions which can be dissolved or suspended in sterile 5 injectable medium immediately before use. They may contain suspending or dispersing agents known in the art. Examples of parenteral administration are intraventricular, intracerebral, intramuscular, intravenous, intraperitoneal, rectal, and subcutaneous 10 administration.

The present invention also relates to a method of decreasing oxidation in a biological sample. Examples of the types of oxidations that can be decreased using this method include lipid peroxidation 15 and oxidations that are mediated by oxygen free-radical processes. The biological sample can be, for example, a cell or a group of cells, e.g. a tissue. The biological sample is contacted with an indole-3-propionic acid or a salt or ester thereof, such as the ones described above. Contacting can be carried out 20 using any suitable method. For example, the indole-3-propionic acid or a salt or ester thereof can be delivered to the extracellular environment surrounding the biological sample. Alternatively, the indole-3-propionic acid or a salt or ester thereof can be 25 introduced directly into a cell, for example, by microinjection. The amount of indole-3-propionic acid or a salt or ester thereof effective to decrease oxidative processes can be determined by conventional 30 methods, such as by delivering varying amounts of the indole-3-propionic acid or a salt or ester thereof and monitoring the concentration of the products of oxidation, such as oxygen free-radicals or the products of lipid peroxidation.

- 14 -

The present invention will be better understood with respect to the following non-limitative examples.

5 Example 1

Tests were conducted to determine whether IPA had neuroprotective activity against the Alzheimer's amyloid peptide ("A β "). Widespread cerebral deposition of this 40-43 amino acid peptide causes extensive 10 degeneration and death of neurons in Alzheimer's Disease.

To illustrate the cytoprotective affects of IPA against the cytotoxic effects of A β , cells of the human neuroblastoma cell line SK-N-SH were used. These 15 cells were exposed to 50 μ M A β (25-35), the actively toxic fragment of A β (Yankner et al., 1990) with or without 50 μ M of IPA. As a control, the experiments were repeated without A β . As a positive control, the well-known anti-oxidant, phenyl-N-t-butylnitrone 20 ("PBN") was substituted for IPA.

The results are shown in Figure 1 as a bar graph illustrating viabilities expressed as percentages. While A β alone has a pronounced cytotoxic effect on the cells, both IPA and PBN have strong 25 protective activity.

Example 2

The experiment of Example 1 was repeated using PC12 rat pheochromocytoma cells. The results are 30 shown in Figure 2 and are essentially identical to the results depicted in Figure 1.

Example 3

The experiment of Example 1 was repeated

- 15 -

using the A β (1-42) peptide using the SK-N-SH human neuroblastoma cell line. The results are shown in Figure 3 and are consistent with those shown with respect to Example 1.

5

Example 4

In order to investigate the possibility that the cytoprotective properties of IPA are also the result, at least in part, of anti-oxidant activity, the 10 levels of malondialdehyde ("MDA"), a marker of lipid peroxidation, in PC12 cells exposed to A β or to oxidative stress were examined. Oxidative stress was delivered by exposing cells to diethyldithiocarbonate ("DDTC"), an inhibitor of superoxide dismutase and an 15 established model of oxidative injury. The PC12 cells were exposed to either amyloid peptide alone or amyloid peptide along with IPA. In other experiments, the cells were exposed to either DDTC alone or DDTC with IPA. The results are shown in Figure 4. It can be 20 seen that IPA significantly decreases the production of malondialdehyde in treated cells, indicating that IPA has anti-oxidant activity. Figure 4 shows both the neuroprotective and the anti-oxidant activities of IPA.

25

Example 5

To further confirm the observations shown in Example 4, we studied whether IPA was effective in preventing death of cells exposed to oxidative stress (DDTC). PC12 neuroblastoma cells were treated with 30 varying amounts of DDTC, with or without varying amounts of IPA. The results are shown in Figure 5. The anti-oxidant activity of IPA is shown by preventing cell death of neuroblastoma cells induced by inhibition of the superoxide dismutase by DDTC. This is in

agreement with the previously presented data that IPA increases the survival of cells exposed to DDTC.

Example 6

5 To determine whether IPA had an effect on A β fibrillogenesis, 150 μ M A β (1-40) was incubated with 300 μ M IPA, sodium salt, dissolved in ultrapure water (i.e., distilled, filtered, and sterilized) at a pH of 7. As a control, the ultrapure water used to dissolve 10 the IPA containing an equivalent amount of sodium chloride was added to 150 μ M A β (1-40) at a pH of 7. In one experiment, each of the solutions (i.e., the solution containing IPA and the control solution) was incubated for 24 hours. In a second experiment, each 15 of the solutions was incubated for 48 hours. At the end of each incubation period, 50 mM glycine-NaOH buffer (pH 9.2) containing 2 μ M thioflavin T was added to each sample (5 μ L) to a final volume of 2 mL. Fluorescence, which is a direct measure of β sheet 20 formation, was measured at an excitation wavelength of 435 nm and an emission wavelength of 485 nm using a Hitachi F-2000 fluorescence spectrometer. The average and standard deviations of the mean of 3 samples per condition were determined, and the results are 25 presented (as bar graphs) in Figure 6A (24 hour incubation) and Figure 6B (48 hour incubation). In both the 24 and 48 hour incubation experiments, the amount of fluorescence is significantly less in the samples containing IPA (labeled A-beta + ipa) relative 30 to control (labeled A-beta). This indicates that less β sheet formation occurred in the samples containing IPA relative to control, which, in turn, indicates that IPA is antifibrillogenic.

- 17 -

Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions and the like can be made without departing from the spirit of the invention and these are therefore considered to be within the scope of the invention as defined in the claims which follow.

REFERENCES

Anderson, J.P., et al., *Neurosci Lett* 128:126-129 (1991).

Behl, C., et al., *Biochem Biophys Res Commun* 186:944-950 (1992).

Behl, C., et al., *Brain Res* 645:253-264 (1994).

Behl, C., et al., *Cell* 77:817-827 (1994).

Burdick, D., et al., *J Biol Chem* 267:546-554 (1992).

Busciglio, J., et al., *Neurobiol Aging* 13:609-612 (1992).

Busciglio, J., et al., *J Neurochem* 61(4):1565-1568 (1993).

Butterfield, D.A., et al., *Biochem Biophys Res Commun* 200:710-715 (1994).

Chartier-Harlin, M.C., et al., *Nature* 353(6347):844-846 (1991).

Copani, A., et al., *Molecular Pharmacology* 47(5):890-897 (1995).

Furuta, A., et al., *Am J Pathol* 146:357-367 (1995).

Glenner, G.G., and Wong, C.W., *Biochem Biophys Res Commun* 120:885-890 (1984).

Goodman, Y., and Mattson, M.P., *Exp Neurol* 128:1-12 (1994).

Haass, C., et al., *Nature* 359:322-324 (1992).

Harris, M.E., et al., *Experimental Neurol* 131:193-202 (1995).

Hensley, K., et al., *Proc Natl Acad Sci USA* 91(8):3270-3274 (1994).

Johnson, H.E., and Crosby, D.G., *J Org Chem*, 25:569ff (1969)

Kemp, D.S., and Vellaccio, F., eds., Organic Chemistry, Worth Publishers, Inc., pp. 371-377 and 1258 (1980).

- 19 -

Kennedy, A.M., et al., Brain 116:309-324 (1993).

Le, W-D., et al., Brain Res 686:49-60 (1995).

Mark, R.J., et al., J Neurosci 15:6239-6249 (1995).

Mattson, M.P., Ann N Y Acad Sci 747:50-76 (1994).

Mattson, M.P., et al., Trends Neurosci 16:409-414 (1993).

Mattson, M.P., et al., J Neurosci 12:376-389 (1992).

Pappolla, M.A., et al., Am J Pathol 140:621-628 (1992).

Pappolla, M. A., and Robakis, N.K., In: Perspectives in behavioural medicine, Alzheimers disease and AIDS. Eds Stein, M., and Baum, M., Academic Press, San Diego, CA, pp. 3-20 (1995).

Pappolla, M.A., et al., Mol Chem Neuropathol 28:21-34 (1996).

Pike, C.J., et al., J Neurosci 13:1676-1687 (1993).

Robakis, N.K., and Pangalos, M.N., Neurobiol Aging 15:S127-129 (1994).

Robakis, N.K., et al., Proc Natl Acad Sci USA 84:4190-4194 (1987).

Sambamurti, K., et al., J Neurosci Res 33:319-329 (1992).

Shoji, M., et al., Science 258:126-129 (1992).

Smith, M.A., et al., Amer J Pathol 145:42-47 (1994).

Tsuzuki et al., Biochem Pharmacol, 41:R5-R8 (1991).

Weidemann, A., et al., Cell 57:115-126 (1989).

Weiss, J.H., et al., J Neurochem 62(1):372-375 (1994).

Yankner, D.A., et al., Science 250:279-282 (1990).

Zhang, Z., et al., Neurosci Lett 177:162-164 (1994).

WHAT IS CLAIMED:

1 1. A method of preventing a cytotoxic
2 effect of amyloid beta protein on cells comprising:
3 exposing the cells to an effective amount of
4 an indole-3-propionic acid or a salt or ester thereof.

1 2. A method according to claim 1, wherein
2 the cytotoxic effect is cell death.

1 3. A method according to claim 1, wherein
2 the cytotoxic effect is increased lipid peroxidation.

1 4. A method according to claim 1, wherein
2 the cytotoxic effect is increased intracellular Ca^{2+} .

1 5. A method according to claim 1, wherein
2 the cytotoxic effect is increased oxygen free-radicals.

1 6. A method according to claim 1, wherein
2 the cells are neuronal cells.

1 7. A method according to claim 1, wherein
2 the cells are present in a human subject and wherein
3 said exposing comprises:
4 administering the indole-3-propionic acid or
5 salt or ester thereof systemically.

1 8. A method according to claim 1, wherein
2 the cells are present in a human subject having a
3 fibrillogenic disease.

1 9. A method of treating a fibrillogenic
2 disease in a human subject comprising:

- 21 -

3 administering an amount of an indole-3-
4 propionic acid or a salt or ester thereof effective to
5 prevent or reverse fibrillogenesis in the human
6 subject.

1 10. A method according to claim 9, wherein
2 said administering is carried out systemically.

1 11. A method according to claim 9, wherein
2 the fibrillogenic disease is Alzheimer's Disease.

1 12. A method according to claim 1, wherein
2 the fibrillogenic disease is a prion-related
3 encephalopathy.

1 13. A method of decreasing oxidation in a
2 biological sample comprising:
3 contacting the biological sample with an
4 effective amount of an indole-3-propionic acid or a
5 salt or ester thereof.

1 14. A method according to claim 13, wherein
2 the biological sample is a cell.

1 15. A method according to claim 13, wherein
2 said decreasing oxidation results in decreasing lipid
3 peroxidation.

1 16. A method according to claim 13, wherein
2 said decreasing oxidation results in decreasing oxygen
3 free-radicals.

1 17. A method for treating diseases or other
2 conditions where free radicals and/or oxidative stress

- 22 -

3 play a role comprising:

4 administering to a patient in need of such
5 treatment an amount of an indole-3-propionic acid or a
6 salt or ester thereof effective for the treatment of
7 said disease or condition.

1 18. A method according to claim 17, wherein
2 said administering is carried out systemically.

1 19. A method according to claim 17, wherein
2 the disease or other condition is selected from the
3 group consisting of Parkinson's Disease, Lewy body
4 dementia, amyo lateral sclerosis, progressive
5 supranuclear palsy, stroke, athrosclerosis, emphysema,
6 and cancer.

1 20. Use of indole-3-propionic acid or a salt
2 or ester thereof in the treatment of diseases
3 associated with the cytotoxic effects of amyloid beta
4 protein.

1 21. Use of indole-3-propionic acid or a salt
2 or ester thereof in the treatment of fibrillogenic
3 diseases.

1 22. Use of indole-3-propionic acid or a salt
2 or ester thereof in the treatment of Alzheimer's
3 Disease, a prion-related encephalopathy, or
4 combinations thereof.

1 23. Use of indole-3-propionic acid or a salt
2 or ester thereof in the treatment of diseases or other
3 conditions where free radicals and/or oxidative stress
4 play a role.

1 24. Use of indole-3-propionic acid or a salt
2 or ester thereof in the treatment of Parkinson's
3 Disease, Lewy body dementia, amyo lateral sclerosis,
4 progressive supranuclear palsy, stroke, athrosclerosis,
5 emphysema, cancer, or combinations thereof.

1 / 4

FIG. 1





FIG. 2



2 / 4

FIG. 3






FIG. 4



3 / 4

FIG. 5



4 / 4

FIG. 6A





FIG. 6B



INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/US 99/03906

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/405

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	<p>CHYAN ET AL: "neuroprotective activity of melatonin against alzheimer beta-amyloid is not mediated by melatonin receptors" SOCIETY FOR NEUROSCIENCE ABST., vol. 24, no. 1-2, November 1998 (1998-11), page 1455 XP002110108 abstract</p> <p>---</p> <p>POEGGELER ET AL: "indole-3-propionate: a potent hydroxyl radical scavenger in rat brain" BRAIN RES., vol. 815, no. 2, January 1999 (1999-01), pages 382-388, XP002110109 page 386 - page 387</p> <p>---</p> <p style="text-align: center;">-/-</p>	1-24
X, P		1-24

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 July 1999	06/08/1999
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Trifillieff-Riolo, S

INTERNATIONAL SEARCH REPORT

Int	tional Application No
PCT/US 99/03906	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MEDVEDEV ET AL: "monoamine oxydase A-inhibiting components of urinary tribulin: purification and identification" J. NEURAL TRANSMISSION, vol. 9, no. 2-3, 1995, pages 225-237, XP002110110 page 225 page 234; figure 4</p>	13-16
A	<p>MATUSZAK ET AL: "reaction of melatonin and related indoles with hydroxyl radicals" FREE RADIC. BIOL. MED., vol. 23, 1997, pages 367-372, XP002110111 page 368; figure 1 page 372, left-hand column</p>	1-24

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/03906

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 1 to 24

are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of Invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.